The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...